Background: The suggested dose of ivermectin is 300 μG/kg/day for onchocerciasis but it has low water solubility and poor oral bioavailability. Aim: To prepare and evaluate a solid lipid-based self-emulsifying drug delivery system of ivermectin. Materials and methods: Based on supersaturated solubility study, oil, surfactant, and co-surfactant were selected. On the basis of ternary phase diagrams and simplex-lattice design, self-emulsifying, drug delivery formulations had been developed and optimized. Ivermectin-excipients compatibility studies were performed using diff erential scanning calorimetry and Fourier transform infrared spectroscopy. Solid self-emulsifying drug delivery formulation was formulated from the optimized batch by surface assimilation method and fi lled into hard gelatin capsules. In vitro release rate and in vivo pharmacokinetic parameters of ivermectin from the capsules were determined. Two-tailed paired t-test/ Dunnett multiple comparison tests were performed for in vivo pharmacokinetic parameter at 95 % of confi dence level. Results: Soybeans oil, tween 80, and span 80 were selected as oil, surfactant, and co-surfactant respectively. The ternary diagrams were shown the maximum area for emulsion in 1:2 surfactant/ co-surfactant ratio. The optimized batch had found with 30 mg ivermectin, 6.17 g soybeans oil, 0.30 g tween 80, and 3.50 g span 80.
The oral route is most convenient for administration of the drug but requires competitive bioavailability for molecule(s). 1 Onchocerciasis or river blindness is a disease caused due to Onchocerca volvulus infection, which is the parasitic worm. Symptoms of onchocerciasis include bumps under the skin, blindness, and severe itching. It is the most common cause of blindness. 2 Ivermectin (IT) treatment for six months is recommended in onchocerciasis. 3 The suggested dose is 300 μG/kg/day for onchocerciasis. 4 However, it is a biopharmaceutical classifi cation system (BCS) class II compound (low solubility and high permeability). 5 It has poor oral bioavailability (50-60%). 6 Therefore, preparation of the oral formulation of IT is quite challenging.
Nowadays, the oral formulation approaches are increased on self-emulsifying drug delivery system (SEDDS) to improve the oral bioavailability of poorly water-soluble drug compounds, especially BCS class II drugs. 7 SEEDS are isotropic mixtures of oil(s) with surfactant (S) and co-surfactant (Co-S). 8 However, the transportation and handling of SEDDS are diffi cult as compared to solid dosage form. 9 In such conditions, the inert solid carrier could be added to form solid SEDDS (SSEDDS) to maintain its self-emulsifying ability via solidification technique.
AIM

PRIMARY AIM
Formulation. To prepare SSEDDS of IT by solidifi cation technique, using lactose as a solid carrier.
SECONDARY ENDPOINT
Assessment. To compare oral in vivo bioavailability of IT SSEDDS with that of IT suspension.
MATERIALS AND METHODS
MATERIALS
IT was received as a gift sample from Pramukh Pharmaceutical Surendranagar, Gujarat, India. Soybeans oil, methanol, hydrochloric acid (HCl), Whatman paper, and dimethyl formaldehyde (DMF) were purchased from Oxford Laboratory, Mumbai, India. Span 80 and tween 80 were purchased from Loba Chemie Lab., Mumbai, India. IT suspension was purchased from Menarini India Pvt Ltd.
SUPERSATURATED SOLUBILITY STUDY
There was 5 mL of oil, S or Co-S were taken in test tubes (Borosil ® ) and an excess quantity of IT mixed together, kept for 48 h in Orbital Shaking Incubator (1HB-164, Remi Equipment Ltd., Vasai, India) at 200 rpm. Thereafter, suffi cient quantity of supernatant was withdrawn and diluted with respective solvents (methanol and DMF). Absorbance at a specifi c wavelength (methanol 246 nm and DMF 266 nm) was measured in Double Beam UV visible Spectrophotometer (LT-2900, Labtronics (I) Pvt. Ltd., Ambala, India). Based on absorbance, solubility was measured by using equation derived from calibration plot (y = 0.0277x + 0.046 for methanol and y = 0.0554x + 0.1308 for DMF). 10 Solubility study of oil (isopropyl myristate and triacetin) and Co-S (Span 20, PEG-400) were performed using methanol as reference solvent, whereas that of oil (soybeans oil, cod liver oil, castor oil, rose oil), S (tween 80, tween 20), and Co-S (span 80) were performed using DMF as reference solvent. Preliminary twenty-seven batches (P1-P27) were formulated with S/Co-S ratio of 1:1, 1:2, and 2:1 w/w ( Table 1) and evaluated for pH, cloud point (Cp) 11 , robustness, thermodynamic stability study, and self-emulsifi cation time (SET).
CONSTRUCTION OF TERNARY PHASE DIAGRAM
In ternary phase diagrams, oil was added to S and Co-S mixture and prepared SEDDS in 200 mL 0.1 N HCl. For generating phase diagram at a specifi c ratio of S/Co-S (i.e. 1:1, 1:2, and 2:1 w/w), 1 mL of prepared bland of S/ Co-S was added into 200 mL of 0.1N HCl and evaluated for self-emulsifi cation ability. A clear and homogenous mixture of oil and S/Co-S were formed using magnetic stirrer (2MLH, Remi Equipments Ltd. Mumbai, India) for 5 min at 
PREPARATION OF LIQUID SEDDS FORMULATIONS
A series of SEDDS formulations were prepared with selected S/Co-S blend and oil by using simplex lattice design. The concentration of oil and S/Co-S ratio were transformed so that minimum concentration corresponds to zero and maximum concentration corresponds to at least one. An accurately weighed IT was placed in a test tube, the added amount of oil, S, and Co-S. Then all components were mixed by magnetic stirrer at 200 rpm until IT was perfectly dissolved. The mixture was kept at room temperature. 13 
CHARACTERIZATION OF SEDDS FORMULATIONS
All the formulations were evaluated for pH, Cp, robustness, thermodynamic stability study, SET, IT content, dispersibility, and in vitro diffusion study. Robustness to dilution was studied by diluting SEDDS to 50, 100, and 1000 times with 0.1N HCl. The diluted SEDDS were stored for 12 h and determined for any signs of phase separation or IT precipitation.
IN VITRO DIFFUSION STUDY OF SEDDS FORMULATIONS
In vitro, IT diffusion study was performed using modifi ed dialysis technique. One end of pretreated cellulose dialysis tubing (7 cm in length; Nipro Medical India Pvt. Ltd) was tied with IP type I dissolution test apparatus (Electro lab, Mumbai, India) using thread and then 0.1 mL of SEDDS (equivalent to 3 mg IT) was placed in it along with 2 mL of dialyzing medium (0.1N HCl). The opposite end of the tube also secured with thread and was rotated freely in the dissolution vessel containing 200 mL dialyzing medium, maintained at 37±0.5°C and stirred at 50 rpm. The samples were withdrawn at different time intervals of 5 min, 10 min, 15 min, 30 min, 45 min, 60 min, and 75 min. 14 
OPTIMIZATION OF SEDDS
Using simplex lattice design and Design-Expert 6.0.8 Portable (State-Ease Inc., USA) optimization of the formulations of SEDDS containing IT was performed. The concentrations of oil (X1), S (X2), and Co-S (X3) were chosen as the independent variables. SET, Cp, and cumulative percentage IT release was taken as variable responses (Y). 15 
IT-EXCIPIENTS COMPATIBILITY STUDY
IT and excipients compatibility studies were performed using differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR):
DSC STUDY DSC study was performed for pure IT, excipients blends, and optimized formulation using differential scanning calorimeter (D-60, Shimadzu, Japan) in an aluminum cell with a nitrogen atmosphere at a fl ow rate of 2 g (mL/min). 16 
FTIR STUDY
IT, excipient blend, and physical mixture of the optimized batch were subjected to FTIR (Shimadzu, Japan) 17 in the scanning range of 350-4600 cm -1 and resolution of 2 cm -1 .
PREPARATION OF SOLID SEDDS FORMULATIONS (SSEDDS)
SSEDDS was formulated from liquid SEDDS by surface assimilation to a solid carrier (lactose) in the ratio of 1:3 (e.g. 1 mL SEDDS and 3 g lactose).
The surface assimilation method was processed by mixing the liquid formulation and lactose carrier in a laboratory blender (Remi Equipment Ltd., Vasai, India). 18 The resulting SSEDDS was subjected to evaluation of bulk density, tapped density, Hausner's Ratio, Carr's index, and angle of repose 19 , then fi lled directly into hard gelatin capsules (size '0') using manual capsule fi lling machine (Remi Equipment Ltd., Vasai, India). Weight variation test and disintegration time for capsule formulation of SSEDDS were also evaluated. 20 
CHARACTERIZATION OF CAPSULE FORMULATION
IN VITRO DISSOLUTION TEST
The release rate of IT from the capsule was determined using IP dissolution test apparatus type II (basket type, Electro lab, Mumbai, India). SSEDDS capsule was placed in a basket at the beginning of every test. The dissolution test was performed using 900 mL of 0.1N HCl (dissolution media), at 37 ± 0.5°C and 100 rpm speed. There was 3 mL sample withdrawn at different time intervals and replaced with the same volume of fresh dissolution media. The samples were fi ltered through Whatman paper. The absorbance of these solutions was measured at 246 nm using UV-Visible photometer. 21 
IN VIVO PHARMACOKINETIC STUDY
Randomized, parallel, experimental study had been approved for laboratory animal usage for research purposes by the Institutional Animal Ethics Committee (IAEC) of School of Pharmacy, RK University, Rajkot, India (Registration No. 131/PO/Re/S/2007/ CPCSEA) and the guidelines for OECD for testing of chemicals were followed. 22 Male Wistar rats weighing 250±75 g fasted for 10-12 h before the experiments. However, rats were allowed free access to water. Twelve rats were divided into two groups of six rats each. The animals were anesthetized using diethyl ether. In vivo pharmacokinetic parameters of IT were determined after oral administration of IT SSEDDS or marketed IT suspension dosage form (0.2 mg/kg of IT) to rats. The blood (100 μL) was collected by the retro-orbital plexus method using capillary at baseline (0 min), at 3 min, 6 min, 12 min, up to 24 h after oral administration of IT formulation. The samples were collected in sodium fl uoride/ EDTA tubes (AG Poly Packs Pvt. Ltd., India) and centrifuged at 5000 rpm for 10 min (Cooling centrifuge, Electro lab, Mumbai, India). The plasma was separated by micropipette (40270280, Thermo electron corporation, Finland) and analyzed by double beam UV visible spectrophotometer. All samples were evaluated for Tmax (time required to reach Cmax), Cmax (maximum plasma concentration), and AUC (area under the curve). 14 Flow diagram for randomized, parallel in vivo pharmacokinetic experimental study is shown in Fig. 1 . 24 InStat (GraphPad, USA) software was used for statistical analysis. The results were considered signifi cant at 95% of confi dence level.
STATISTICAL ANALYSIS
RESULTS
Solubility study results (Table 2) suggested that IT had the highest solubility in soybeans oil, tween 80, and span 20. Tween 80 and span 80 were selected as S and Co-S, respectively. Span 80 was selected as a Co-S in place for span 20 with consideration of their HLB values. All SEDDS formulations of a preliminary study had shown desirable pH (in the range of 6.1-6.5; neither too acidic nor too basic). The cloud points of all 27-preliminary batches had found higher (in the range of 60-74°C) indicated good stability. SET of all the preliminary formulations were less than 4 s.
Ternary phase diagrams were constructed with S/ Co-S ratio of 1:1, 1:2, and 2:1. Figure 2 revealed that the maximum area for emulsion was in the 1:2 ratio of S/Co-S. Therefore, further trial and work proceeded through consideration of this ratio. All SEEDS formulations were stable (no phase separation) on visual observation, during the heatingcooling cycle, centrifugation, and freeze-thaw cycle. All formulations had a translucent appearance, robustness, and dispersibility grade A (rapidly forming, within one minute, emulsion, having a clear or bluish appearance). The other physicochemical characterizations of SEDDS formulations are reported in Table 3 . The results of in vitro diffusion study showed that IT had good diffusion and dissolution from SEDDS dosage form which allows a quicker release of it into the aqueous phase than marketed formulation (p = 0.0453, q = 3.701) ( Table 4) . As shown in Fig. 3 inverse relationship exists between SET, t 90 (time required to release 90% of IT) and Cp. However, the quantity of IT diffused was increased. Overlay between t 90 , SET, and Cp (dependent variables) had shown optimized region (Fig. 4) . The polynomial mathematical models were prepared as Eqs 1, 2, and 3: 
where, A = soybeans oil, B = tween 80, C = span 80, R 2 = correlation coeffi cient, Sv = the signifi cance value of mathematical model, and ε = practical error. The above statistical data indicated that the mathematical model had good accuracy.
One checkpoint cum optimized batch (F8) based on the shared area in overlay contour plot was performed after generating fl ag chart.
DSC study showed that endothermic peaks of IT + excipients mixture had started with 156.50°C, and the end of 165.29°C (Fig. 5) . FTIR study of the optimized batch was exhibited peaks at 3450 cm -1 , 1750 cm -1 , and 1175 cm -1 , which are peaks of the functional group -OH (Phenolic), ester, and ether of IT, respectively (Fig. 6) .
The bulk density, tapped density, Hausner's Ratio, Carr's index, and angle of repose of SSEEDS had found 0.714±0.002 g/mL, 0.834±0.002 g/mL, 1.161±0.001, 14.29±0.003, and 16.11±0.001°, respectively. The weight of capsule was in the range 298±2 mg for weight variation test while disintegra- tion time for capsule formulation was 6.18 ± 2 min.
The total plasma concentration of IT in SSEDDS was higher than that in IT suspension ( Table 5) .
DISCUSSION
All 27-preliminary formulations showed robustness for emulsifi cation after specifi c dilution (within one min), had a clear or bluish appearance. It ensures the thermodynamic stability of formulations and showing Grade-A type SEDDS (Grade A: Rapidly forming). 23 With respect to physical properties of prepared SEEDS, the choice oil, S, and Co-S were quite appropriate for formulation study.
Cp of prepared SEDDS formulations (F1 -F8) was found to be higher than 60°C. Prepared SEDDS were stable at physiological temperature without risk of phase separation. 11 With respect to the results of physicochemical properties of SEDDS, the study succeeded in the preparation of SEDDS of IT.
All the characteristic peaks of IT and excipients mixture of the optimized formulation were identical with that of pure IT. IT and excipients were compatible with each other. 25 Both DSC measurements and FTIR analysis suggested that IT in the SSEDDS may be in the molecular dispersion state.
Hausner's Ratio, Carr's index, and angle of repose of prepared SSEEDS were < 1.125, < 15, and < 25 respectively. Physical properties revealed that SSEEDS had free good fl owing properties. 19 The study was prepared SSEDDS consisted of wellseparated particles with a smooth surface.
The higher AUC and Cmax value of IT was found in SSEDDS formulation than in marketed suspension preparation of IT. AUC of IT from SSEDDS was about two-fold higher than that of IT suspension. The fast rate of diffusion and dissolution may also infl uence the bioavailability of IT. However, Tmax value of IT from SSEDDS was not different from those of IT suspension. SSEDDS was increased in the bioavailability of IT compared to the marketed suspension formulation. 14 In respect to the data of in vivo pharmacokinetic study, SSEDDS had preserved the self-emulsifi cation performance of liquid SEDDS.
Six rats were used for the study in two groups to evaluate in vivo pharmacokinetics data. Till date, available studies as simvastatin SEDDS is used six rats in four groups 14 , ketoconazole SEDDS is used four rats in six groups 12 , simvastatin self-micro emulsifying drug delivery system is used three dogs in three groups 10 , and candesartan cilexetil self-nano emulsifying drug delivery system is used six rats in three groups 11 . Moreover, the sample size is not an issue, the more important is effective research design. 26 In respect to the data of the study, the fi nding was justifi ed the sample size.
In limitations of the study, for example, basic science animal model was applied to human. Only male Wister rats were used. However, sex of animal infl uences the pharmacokinetics of drugs. There were α-errors observed in results of in vivo pharmacokinetic study because of small sample size. The larges human study is recommended to state the hypothesis strongly.
CONCLUSION
The experimental formulation study concluded that it was possible to improve the bioavailability of ivermectin using the solid self-emulsifying drug delivery system. Solid self-emulsifying drug delivery system was provided a useful oral solid dosage form for the poorly water-soluble drug, ivermectin. All data are presented as mean ± SD, n = 5. 
